We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

15 hedge funds and large institutions have $4.75M invested in Summit Therapeutics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

43% more capital invested

Capital invested by funds: $3.32M → $4.75M (+$1.43M)

15% more funds holding

Funds holding: 13 → 15 (+2)

1.89% less ownership

Funds ownership: 3.51% → 1.62% (-1.9%)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$161K
2
Renaissance Technologies
Renaissance Technologies
New York
+$44.7K
3
SWM
SeaCrest Wealth Management
New York
+$35.4K
4
Deutsche Bank
Deutsche Bank
Germany
+$18.9K
5
VF
Virtu Financial
New York
+$17.6K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$513K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$12.6K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$12K
4
UBS Group
UBS Group
Switzerland
-$1.67K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPU
1
Lansdowne Partners (UK)
United Kingdom
$2.92M – – –
PC
2
Polar Capital
United Kingdom
$641K – – –
Morgan Stanley
3
Morgan Stanley
New York
$417K +$72 +44 +0%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$321K -$12.6K -7,660 -4%
Bank of New York Mellon
5
Bank of New York Mellon
New York
$180K +$161K +98,396 New
Renaissance Technologies
6
Renaissance Technologies
New York
$140K +$44.7K +27,230 +55%
Citadel Advisors
7
Citadel Advisors
Florida
$44K +$9.48K +5,782 +32%
SWM
8
SeaCrest Wealth Management
New York
$41K +$35.4K +21,597 +2,979%
Deutsche Bank
9
Deutsche Bank
Germany
$21K +$18.9K +11,500 New
VF
10
Virtu Financial
New York
$20K +$17.6K +10,751 New
Group One Trading
11
Group One Trading
Illinois
$1K – – –
PFBT
12
Parkside Financial Bank & Trust
Missouri
$1K – – –
LFG
13
Larson Financial Group
Missouri
$1K +$1.07K +654 New
Point72 Asset Management
14
Point72 Asset Management
Connecticut
– -$513K -445,991 Closed
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$12K -10,569 Closed
UBS Group
16
UBS Group
Switzerland
– -$1.67K -1,021 -90%

SMMT Hedge Fund Activity: Q1 2019 in Review

15 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2019, worth a combined $4.75M — up 43% from $3.32M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SMMT positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $161K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $513K sold.

  • 15 institutional investors held Summit Therapeutics (SMMT) as of Q1 2019, up from 13 in Q4 2018.
  • Funds reported $4.75M of Summit Therapeutics stock for Q1 2019, up 43% quarter-over-quarter.
  • 4 funds opened new Summit Therapeutics positions in Q1 2019 and 2 closed out, a net change of +2 holders.
  • The largest Summit Therapeutics buyer in Q1 2019 was Bank of New York Mellon, an estimated $161K added.
  • The largest Summit Therapeutics seller in Q1 2019 was Point72 Asset Management, an estimated $513K sold.

Based on aggregated 13F filings for Q1 2019.